DAX-0,13 % EUR/USD0,00 % Gold-0,08 % Öl (Brent)+0,66 %

Advanced Biotherapy Enters Into Share Purchase and Debt Restructure Agreement - 500 Beiträge pro Seite


Beitrag schreiben

Begriffe und/oder Benutzer

 

Advanced Biotherapy Enters Into Share Purchase and Debt Restructure Agreement
Tuesday August 29, 7:04 pm ET

CHICAGO--(BUSINESS WIRE)--Aug. 29, 2006--Advanced Biotherapy, Inc. (OTCBB: ADVB - News) announced today that it has entered into an agreement to raise $6,500,000 through a sale of stock to Richard P. Kiphart, a board member, and Christopher Capps and other related parties, at $.015 per share. In addition, Mr. Kiphart and other debt holders will convert their debt at $.015 per share resulting in Mr. Kiphart having personal control over approximately 80% of ADVB shares. Immediately following the infusion of capital, payables will be retired by both the use of cash as well as the conversion of some portion to stock at the same $.015 price. It is estimated that ADVB will be virtually debt free and have approximately $6.0 million in cash, following completion of the transaction.

ADVERTISEMENT
click here
The company will move its headquarters to Chicago, Illinois, from Woodland Hills, California, and Christopher W. Capps has been appointed Chief Executive Officer and Mr. Kiphart non-executive Chairman of the Board. It is the intention of management to maintain the current intellectual property portfolio and seek partnership with other companies for the licensing thereof. Management believes that interest earned on the fully subscribed amount of new capital, once received, will allow the company to operate on a profitable basis. Mr. Kiphart has funded $1,100,000 and expects the balance of the $6,500,000 to be funded in approximately thirty days upon satisfaction of certain conditions in the definitive agreement. In addition, ADVB intends to pursue acquisitions that it believes can help it maintain its profitable operations.

The company intends to register as soon as possible a rights offering allowing existing stockholders to purchase ten shares of common stock at $.015 per share for every share held.

Mr. Kiphart said, "I am excited to be more deeply involved with Advanced Biotherapy. The company has terrific intellectual property and now has sufficient capital to allow it to be profitable and consider acquisitions on a going forward basis."

Thomas J. Pernice, a member of the Board of Directors, stated, "On behalf of Richard Kiphart, the Board of Directors and the new management team, I would like to commend and thank Edmond Buccellato for his extraordinary personal efforts in establishing the company's extensive patent portfolio and enabling it to reach a stage that allows the company to pursue licensing and other partnership opportunities."

About Advanced Biotherapy

The Company, a pioneer in anticytokine therapy, has demonstrated the effectiveness of its pioneering scientific strategy by conducting investigational clinical trials treating patients suffering from AIDS, multiple sclerosis, rheumatoid arthritis, corneal transplant rejection and certain autoimmune skin conditions, including alopecia, all Th1 mediated autoimmune diseases which appear to have the same proinflammatory Th-1 activity. Advanced Biotherapy is headquartered in Chicago with laboratories in Columbia, Maryland. The company has an extensive patent portfolio including 7 issued patents.

Forward-Looking Statements

Statements made in this news release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the anticipated results or other expectations expressed in our forward-looking statements. Some of these forward-looking statements may be identified by the use of words in the statements such as "anticipate," "estimate," "could" "expect," "project," "intend," "plan," "believe," "seek," "should," "may," "assume," "continue," variations of such words and similar expressions. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict. We caution you that our performance and results could differ materially from what is expressed, implied, or forecast by our forward-looking statements. Future operating results and the Company's stock price may be affected by a number of factors, including, without limitation: (i) availability of capital; (ii) opportunities for joint ventures and corporate partnering; (iii) opportunities for mergers and acquisitions to acquire non-bio technology businesses or to expand the Company's biotechnology base; (iv) regulatory approvals of preclinical and clinical trials; (v) intellectual property matters (patents); and (vi) competition. Readers are cautioned not to place reliance on these forward-looking statements, which speak only as of the date the statements were made. See the Company's public filings with the Securities and Exchange Commission for further information about risks and uncertainties that may affect the Company and the results or expectations expressed in our forward-looking statements, including the section captioned "Factors That May Affect The Company" contained in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such forward-looking statements. Except as required under federal securities laws and the rules and regulations of the SEC, we do not intend to update publicly any forward-looking statements to reflect actual results or changes in other factors affecting such forward-looking statements.

GRÜßE
ganz frisch!



Form 8-K for ADVANCED BIOTHERAPY INC

30-Aug-2006

Entry into a Material Definitive Agreement, Unregistered Sale of Equity S


Item 1.01. Entry Into a Material Definitive Agreement.

On August 28, 2006, the Registrant (or "Company") and Richard P. Kiphart ("Noteholder"), a director of the Company, entered into a Share Purchase and Debt Restructure Agreement ("Agreement"). The parties entered into the Agreement for the purpose, among others, to restructure the Company's long-term and short-term debt into equity and to sell Company common stock to the Noteholder for cash to be used for working capital and possible acquisitions. The closing of the transactions ("Transactions") contemplated by the Agreement is subject to satisfaction of certain conditions which have not been satisfied as of the date of this Form 8-K, but are expected to be completed in approximately thirty days.

The Company's subordinated convertible debt due September 30, 2004 ("2000-2004 Convertible Notes") in the approximate aggregate principal amount of $7,805 as of June 30, 2006, subordinated convertible pay-in-kind notes due June 1, 2006 ("2002-2006 Convertible Notes") in the approximate aggregate principal amount of $4,740,466 as of June 30, 2006, and term notes due June 30, 2006 in the approximate aggregate principal amount of $245,637, have matured and the Company lacks funds to repay those notes. The Company also has outstanding subordinated convertible pay-in-kind notes due September 30, 2007 ("2003-2007 Convertible Notes"), in the approximate aggregate principal amount of $1,095,413 as of June 30, 2006, subordinated convertible pay-in-kind notes due September 30, 2009 ("2005-2009 Convertible Notes") in the approximate aggregate principal amount of 267,213 as of June 30, 2006, and other outstanding promissory notes (collectively, "Demand Notes") in the approximate aggregate principal amount of $15,746, as of June 30, 2006, respectively.

A. Sale of Company Shares. Subject to the terms and conditions of the Agreement, the Company agreed to sell an aggregate of 433,333,333 shares ("New Shares") of Company common stock, $0.001 par value, at $0.015 per share to the Noteholder, certain family members of the Noteholder, Christopher Capps (the Company's new President and Chief Executive Officer) and other prospective board members, for the aggregate sum of $6,500,000 ("New Capital"). The Company has received $1.1 million of the New Capital from the Noteholder as of the date of this Form 8-K for which the Noteholder acquired 73,333.333 shares of Company common stock. The balance of the New Capital will be paid to the Company upon the Company filing an amendment to its Certificate of Incorporation ("Amendment to Certificate") that increases the number of authorized shares of Company common stock from 200,000,000 to 2,000,000,000 shares of common stock. Such Amendment has been approved by the Company's board of directors. Holders of a majority of the outstanding common stock have agreed to vote in favor of the Amendment. The Company expects to file the Amendment to Certificate with the Delaware Secretary of State on the 20th day after the Company's Information Statement has been mailed to its stockholders notifying them about the action taken by written consent of the holders of a majority of outstanding shares of common stock to approve the Amendment to Certificate, and the action to file such Amendment. The mailing of the Information Statement to stockholders is expected to be made on or about September 11th.

B. Adjustment of Conversion Price of Convertible Notes and Other Debt. Pursuant to the Agreement, the Company agreed to adjust the conversion price of all outstanding Convertible Notes, including, without limitation, the 2002-2006 Convertible Notes, the 2003-2007 Convertible Notes and the 2005-2009 Convertible Notes, and agreed to adjust the conversion price of certain convertible Demand Notes, and agreed to permit the holders of the Company's other Demand Notes to exchange those notes, in each case, for one (1) share of Company common stock for each $0.015 amount of indebtedness.

C. Conversion of Company Debt into Equity. The Noteholder agreed to convert all of his Convertible Notes and Demand Notes into shares of common stock at the same $0.015 per share conversion price. Subject to the filing of the Amendment to Certificate in accordance with the Agreement, the Noteholder will receive approximately 360,980,730 shares of the Company common stock upon conversion of his Convertible Notes and Demand Notes. The other holders ("Other Holders") of Convertible Notes, Demand Notes and certain indebtedness owed by the Company have agreed to convert the entire principal amount thereof, together with accrued interest thereon, into shares of Company common stock, at the price of $0.015 per share, all effective as of the closing of the Transactions. The Other Holders will receive approximately 35,318,000 shares of Company common stock upon such conversions.

Page 2 of 7

D. Stockholder Rights Offering. The Noteholder agreed to cause the Company to commence a stockholder rights offering ("Rights Offering") for shares of Company common stock, to be offered to the Company's stockholders, excluding the Noteholder, his affiliates and related parties, at a price of $0.015 per share. The Rights Offering will provide that each stockholder will have the right to purchase up to ten (10) shares of Company common stock for each one (1) share then held by such stockholder, at $0.015 per share. The Rights Offering is . . .


Item 3.02. Unregistered Sales of Equity Securities.

The New Shares are being sold pursuant to the exceptions provided by
Section 4(2) of the Securities Act of 1933, as amended ("Act") and Regulation D, promulgated thereunder. The Noteholder and the other individuals who acquired, or acquire, New Shares are or will be each an "accredited" investor, as that term is defined in Rule 501 in Regulation D of the Act. No general solicitation or advertising was employed by the Company, or anyone else associated with the Company in connection with the placement of the New Shares. No commissions were paid. The certificates representing the New Shares will bear appropriate restrictive legends. All of the shares being acquired by the Noteholder and Other Holders pursuant to conversion or other exchange are being issued pursuant to an exemption under the Act and applicable securities laws. All certificates representing the shares of common stock to be issued to Noteholder and Other Holders will bear appropriate restrictive legends.

According to the Noteholder, the Noteholder and the other individual purchasers of New Shares used, or will use, personal funds to acquire the New Shares.



Item 5.01. Changes in Control of Registrant.

Upon receipt by the Company of the New Capital, the Noteholder will acquire from the Company shares of Company common stock constituting a majority of the issued and outstanding shares of Company common stock, which will result in a change in control with respect to the stock ownership of the Company such that the Noteholder will hold the majority of the issued and outstanding of the Company common stock. As a result of his share ownership, the Noteholder will be able to elect all of the directors who comprise the Board of Directors, which represents a change in the majority control of the Board. Pursuant to the Agreement, the Noteholder will acquire approximately 83% of the issued and outstanding shares of the Company after taking into account the New Capital and conversion of all Company Convertible Notes, Demand Notes, and other approved Company indebtedness into shares of Company common stock.



Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

The Board of Directors approved the appointment of Richard P. Kiphart as the new Chairman of the Board, Christopher W. Capps as the new President and Chief Executive Officer, and Thomas J. Pernice as Secretary and Treasurer. These appointments are effective as of August 28, 2006. There are no written employment agreements between the Company and such officers/directors.

Since June, 2002, Richard P. Kiphart (65) has served as a member of the Company's Board of Directors. He currently serves as Chairman of the Board of Saflink (SFLK Nasdaq) and a member of the Board of Directors of First Data Corp. (FDC-NYSE). Mr. Kiphart is the Head of Corporate Finance for the Investment Firm of William Blair & Company, L.L.C. Mr. Kiphart has been with William Blair for over 36 years. Mr. Kiphart received his B.A. from Dartmouth College and his M.B.A. from Harvard Business School.

Since September 2005, Christopher W. Capps (24) has served as President and CEO of KVG Partners, a private equity firm. Mr. Capps received his B.A. in History from Southern Methodist University.

Since April 2001, Thomas J. Pernice (44) has served as the Treasurer and Secretary of the Company and as a member of the Board of Directors. Mr. Pernice has served as a senior executive in government and industry for more than 22 years. He is Chief Executive Officer and Founder of Modena Holding Corporation since 1999, an innovative consulting company specializing in business development strategies, mergers and acquisitions and finance, and specializing in strategic communications and government relations for private and public companies. Modena has strategic alliances with the DCI Group, an international public relations firm based in Washington, D.C., The Abraham Group, a strategic consulting practice founded by former U.S. Energy Secretary Spencer Abraham also based in Washington, D.C., and also advises Mullin-TBG, the nation's leading provider of deferred executive compensation services. He has served for more than nine years as a Presidential appointee in three U.S. Presidential Administrations; first as a White House Staff member in the Reagan Administration, a Senior White House staff member in the Bush 41 Administration and most recently as a Senior Advisor in the Bush 43 Administration to the U.S. Department of Energy. After his public service in the Reagan and Bush Administrations, Mr. Pernice served for eight years as Vice President in the Office of the Chairman for the conglomerate of publicly and privately held business interests of David H. Murdock.

Page 4 of 7

Mr. Pernice earned a Bachelor of Arts degree in Broadcast Journalism from the University of Southern California in 1984.

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports we file with the Securities and Exchange Commission ("SEC") contain forward-looking statements relating to, among other things, the Transaction, and our future performance, our business, and future events. All statements other than statements of historical facts are forward-looking statements, including, without limitation, any statements regarding future performance. Some of these forward-looking statements may be identified by the use of words in the statements such as "anticipate," "estimate," "could" "expect," "project," "intend," "plan," "believe," "seek," "should," "may," "assume," "continue," variations of such words and similar expressions. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict. We caution you that our performance and results could differ materially from what is expressed, implied, or forecast by our forward-looking statements. Future operating results and the Company's stock price may be affected by a number of factors, including, without limitation: (i) availability of capital;
(ii) opportunities for joint ventures and corporate partnering; (iii) opportunities for mergers and acquisitions to acquire non-biotechnology revenue generating businesses, or to expand the Company's biotechnology base; (iv) regulatory approvals of preclinical and clinical trials; (v) intellectual property matters (patents); and (vi) competition. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section entitled "Item 1. Business," and all subsections therein, including, without limitation, the subsections entitled, Technical Background, Government Regulation, Federal Drug Administration Regulation, Competition, and Factors That May Affect the Company, and the section entitled "Market for Registrant's Common Stock and Related Stockholder Matters," all contained in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such forward-looking statements. Except as required under federal securities laws and the rules and regulations of the SEC, we do not intend to update publicly any forward-looking statements to reflect actual results or changes in other factors affecting such forward-looking statements.



Item 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Designation Description of Exhibit

10.17 Share Purchase and Debt Restructure Agreement

99.1 Press Release dated August 29, 2006
The Company has no long-term debt and has approximately $6.2 million in cash, as of October 12, 2006.





Advanced Biotherapy, Inc. Completes Stock Sale and Debt Conversion
Friday October 13, 7:10 pm ET

CHICAGO--(BUSINESS WIRE)--Advanced Biotherapy, Inc. (OTCBB:ADVB - News) announced today that it has completed the sale of common stock to Richard P. Kiphart and other new investors in the amount of $5.4 million. This investment, plus the previous $1.1 million invested by Richard P. Kiphart around August 28, 2006, completes the $6.5 million capital raise previously announced by the Company. The Company also announced the conversion of all convertible notes, other promissory notes and accrued salaries owed by the Company, except for a nominal amount which was paid out in cash. The Company has no long-term debt and has approximately $6.2 million in cash, as of October 12, 2006.

ADVERTISEMENT
About Advanced Biotherapy

The Company, a pioneer in anticytokine therapy, has demonstrated the effectiveness of its pioneering scientific strategy by conducting investigational clinical trials treating patients suffering from AIDS, multiple sclerosis, rheumatoid arthritis, corneal transplant rejection and certain autoimmune skin conditions, including alopecia, all Th1 mediated autoimmune diseases which appear to have the same proinflammatory Th-1 activity. Advanced Biotherapy is headquartered in Chicago with laboratories in Columbia, Maryland. The company has an extensive patent portfolio including 7 issued patents.


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um eine ältere Diskussion, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier eine neue Diskussion.